1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
China Biotech Services Holdings Limited

China Biotech Services Holdings Limited

HHKEX:8037
0.50
HKD
+0.00
(-1.00%)
382.48MMarket Cap
China Biotech Services Holdings Limited
HKEX:8037
(Hong Kong Exchange)

Recent

price

0.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
11.89
4.89
1.09
2.5
0.82
0.12
0.12
0.13
0.08
0.06
0.68
0.65
1.92
0.22
0.07
0.08
- -
Revenue per Share
-6.19
-0.96
-1.79
-0.84
-0.97
-0.21
-0.07
-0.08
-0.07
-0.1
0.03
0.02
0.27
-0.1
-0.2
-0.07
- -
Basic EPS, GAAP
0.39
-0.43
-1.22
-0.64
-0.5
-0.32
-0.05
-0.08
-0.02
-0.04
0.31
0.03
0.38
0.14
-0.21
-0.2
- -
Free Cash Flow per Basic Share
0.25
0.27
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
- -
- -
Dividend per Share
3.18
5.84
3.92
3.65
1.33
0.49
0.34
0.3
0.35
0.3
0.36
0.41
0.63
0.48
0.27
0.2
0.41
Book Value per Share
3.18
5.84
3.92
3.5
1.11
0.34
0.25
0.24
0.3
0.08
0.14
0.2
0.43
0.3
0.12
0.04
0.24
Tangible Book Value per Share
14
17
24
25
85
294
707
801
882
961
968
965
963
963
968
976
963
Basic Weighted Avg Shares
161
84
26
61
70
34
87
105
70
59
656
624
1,852
212
71
74
- -
Sales/Revenue/Turnover
-24.6
-25.16
-146.22
-15.89
-30.67
-100.55
-48.32
-36.57
-95.75
-141.96
30.46
30.33
45.87
-55.96
-209.36
-102.41
- -
Operating Margin (%)
5
4
3
2
3
6
7
7
8
20
40
68
66
56
21
16
- -
Depreciation Expense
-84
-16
-44
-21
-83
-62
-50
-63
-64
-99
30
19
258
-95
-198
-69
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.35
26.62
18.23
- -
- -
- -
- -
Effective Tax Rate (%)
-52.06
-19.56
-164.66
-33.78
-118.28
-182.46
-57.93
-59.94
-91.39
-166.93
4.6
3.11
13.94
-45.03
-281.02
-93.57
- -
Profit Margin (%)
-13
90
62
88
100
201
103
136
202
33
174
50
336
102
-130
-266
-54
Working Capital
3
- -
- -
- -
- -
- -
3
5
2
6
83
4
65
6
43
148
4
LT Debt
49
147
98
107
198
343
275
251
319
313
512
466
827
491
242
156
381
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-32.65
21.9
78.81
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-20.93
-15.46
-25.88
- -
- -
- -
- -
Return on Capital (%)
-98.24
-17.8
-36.71
-20.51
-60.14
-25.4
-17.1
-24.23
-22.2
-32.24
9.54
5.25
51.72
-17.92
-54.46
-30.14
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
95
163
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
6
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
963
956
956
Market Capitalization
626
736
382

Working Capital

HKD

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
261
157
Cash, Cash Equivalents & STI
- -
72
33
Accounts Receivable, Net
- -
20
12
Inventories
- -
9
6
Total Current Liabilities
- -
159
211
Payables & Accruals
- -
- -
- -
ST Debt
- -
95
163
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.16%
-11.72%
-35.75%
Free Cash Flow
-8.97%
152.67%
-5.95%
Net Income, GAAP
103.24%
220.19%
-65.29%
Sales/Revenue/Turnover
117.46%
8.18%
4.25%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
212
2024
- -
- -
71
2025
- -
- -
74

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.1
2024
- -
- -
-0.2
2025
- -
- -
-0.07

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
China Biotech Services Holdings Limited (8037.HK), an investment holding company incorporated in the Cayman Islands in 2003 and continued in Bermuda, with principal operations headquartered in Hong Kong, provides medical laboratory testing and health check services; tumor immune cell therapy and health management services; sale and distribution of health-related and pharmaceutical products; insurance brokerage services; boron neutron capture therapy (BNCT) treatment services; money lending; logistic services; and property investment activities, primarily serving customers in Hong Kong and the People's Republic of China through its reportable segments of medical and health-related services, immunotherapy, pharmaceutical products, insurance brokerage, BNCT, and others. The company operates advanced laboratory facilities utilizing technologies such as polymerase chain reaction (PCR) for infectious disease control, genetic screening, and clinical diagnostics, alongside immunotherapy offerings including immune cell storage and tumor treatments, with BNCT focused on innovative cancer therapies via subsidiaries like Pengbo (Hainan) Medical Technology Co., Ltd. In recent developments, the company entered a strategic cooperation framework agreement with Shenzhen BGI Technology Co., Ltd. in February 2025 to advance biotechnology initiatives; secured conditional capital injections into Pengbo (Hainan) totaling up to RMB80 million from investors including Shenzhen BGI Songhe Biotechnology No. 1 Private Venture Capital Investment Fund Partnership and Hubei Weiyou Equity Investment Partnership; issued new convertible bonds in December 2024 amounting to US$6 million with a reduced conversion price of HK$1.20 per share following a substantial modification and partial redemption of prior 2022 bonds; recognized significant impairments on property, plant and equipment, intangible assets, and right-of-use assets amid BNCT equipment damage from a rainstorm in Hainan (with partial insurance compensation received); and continues negotiations for debt extensions and additional financing to address net current liabilities as of December 31, 2024.